Anterios, which is developing a topical formulation of botulinum toxin, filed on Tuesday with the SEC to raise up to $58 million in an initial public offering.
Revance Therapeutics (RVNC), which is also developing a topical formulation of botulinum toxin, IPO'd in February 2014. It popped 68% on its first day and continued upward, but now trades 30% above its offer price.
The New York, NY-based company, which was founded in 2006, plans to list on the NASDAQ under the symbol ANTE. Anterios initially filed confidentially on January 7, 2015. Stifel and RBC Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
